Selinexor (Xpovio®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Xpovio blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion.
Selinexor is an oral drug approved for use in combination with dexamethasone by relapsed or refractory myeloma patients who have received at least 4 prior therapies and who are resistant to at least 2 proteasome inhibitors, at least 2 immunomodulatory drugs, and to an anti-CD38 monoclonal antibody.
|Developed By||Karyopharm Therapeutics|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
March 10, 2020